Reply to "Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the "minimal disease activity" parameter"

Dermatol Ther. 2022 Aug;35(8):e15644. doi: 10.1111/dth.15644. Epub 2022 Jul 4.

Authors

Giulia Murgia^{1

2}, Carlo Alberto Maronese^{1

2}, Carlo Giovanni Carrera¹, Angelo Cattaneo¹, Angelo Valerio Marzano^{1

2}

Affiliations

¹ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

PMID: 35708288
DOI: 10.1111/dth.15644

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Psoriasis* / diagnosis
Psoriasis* / drug therapy
Ustekinumab* / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
guselkumab
Ustekinumab